Treatment of endometriosis with the GnRH agonist nafarelin acetate
Other
OA: closed
CC0
⤵ 5 in-corpus citations
AI-generated summary
This review details a multicenter study of nafarelin acetate for endometriosis, including its scoring system and symptom relapse after treatment with nafarelin and danazol.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Additional details of a multicenter study of nafarelin acetate with particular attention to a unique endometriosis scoring system utilized are reviewed. Additional information regarding the relapse of symptoms of 10 patients treated with nafarelin and danazol during a 6- to 12-month follow-up interval is described. Transient decreases in leukocytes previously reported by other investigators were observed in 3 of 8 patients, but appear to represent a laboratory artifact.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (5)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Ovulation suppression for endometriosis for women with subfertility 2007
- Ovulation suppression for endometriosis 2003
- The use of GnRH agonists in the treatment of endometriomas with or without drainage 1996
Source provenance
- europepmc
- last seen: 2026-10-14T06:08:39.101224+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:03:51.313027+00:00
License: CC0
· commercial use OK